LEADERS FREE II: BioFreedom™ Pivotal Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1203 participants.
Also called NCT02843633
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,203 participants
- Sponsor
- Registry
-
NCT02843633
-
- Other papers using this trial's data
- Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Canada, Denmark, France, Germany, Italy, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT02843633. Allocation not applicable; no masking; primary purpose treatment. Start 2017-02-14 (actual); primary completion 2018-10-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LEADERS FREE II: BioFreedom™ Pivotal Study
- Condition
- Acute Coronary Syndrome
- Condition
- High Bleeding Risk
- Intervention (Device)
- BioFreedom™ Drug Coated Coronary Stent System
- Intervention (Drug)
- Antiplatelet Drug
- Lead sponsor
- Biosensors Europe SA
Record details
- Record id
cardio:ct-nct02843633- Content hash
6ec44d4a47a6c6ce6ca7953b86e67c1912bd605c432c0cc6f1e5ecdf0d5c070a